The size of the European antibiotics market is forecasted to be growing at a CAGR of 4.2% between 2021 to 2026.
The European antibiotics market is projected to be driven by the factors such as the high prevalence of infectious diseases in the region, lower respiratory infectious infection, malaria, pneumonia, and tuberculosis, and proliferation of chronic diseases. Over the years in Europe, the growing disease burden is compelling government and non-government bodies to invest in providing better healthcare facilities for the people in the region is encouraging market growth. Besides, the increasing efforts of the regional pharmaceutical companies to develop novel therapies to treat infectious diseases are most likely to witness a significant impact on the antibiotics market growth over the forecast period. Also, a significant rise in the demand for antibiotics is attributed to the increasing incidence of infectious diseases in the countries such as Germany, the UK, and Italy are expected to uplift the European antibiotics market growth.
On the other hand, collaborations of pharmaceutical companies for the development of advanced therapies reduce the cost burden of the drug development process. Moreover, supportive investment and funding by the government and private organizations for improving the healthcare infrastructure in the region encourage market development. However, favorable government regulatory policies to expedite the approval process and growing research and development activities on Antibiotics are expected to witness significant European antibiotics market growth. Besides, the collaborations in the regional players and active participation of key market players boost the market growth.
The primary concern for the antibiotic market growth is that the monoclonal antibodies' development process is a time-consuming and complicated procedure that is expected to restrain the European antibiotics market growth. On the other hand, the development of antibiotic resistance and spike in drug approval costs is expected to restrain the antibiotic market growth. However, the variations in the antibodies affect the results of research and clinical screening tests. Furthermore, innovations require massive bioreactors and large bioreactor filtration systems for antibody processing, putting additional strain on market participants. Besides that, the lack of requirements for their validity reproducibility across all antibody products hampers the European antibiotics market growth.
Impact of COVID-19 on the Europe Antibiotics Market:
The COVID-19 outbreak identified in a meat market in Wuhan (China) and has had a negative impact on the intake of animal-derived food products; this can be due to the prevalence of numerous diseases, such as swine flu, Zika virus, Hantavirus, and the current bird flu, among others, that have originated in poultry. Furthermore, significant corporations' antimicrobial stewardship activities could be hampered by heavy workloads and changing goals relevant to COVID-19. As a result, the demand for animal-sourced goods is expected to decline. During the ban on transportation, Trade barriers in different countries and the adoption of alternate sources, such as plant-based foods, are likely to limit market expansion.
However, after the unlock of lockdown, the COVID-19 outbreak boosted antibody market growth in Europe during the COVID-19 outbreak period. Antibiotic research has been boosted as a result of attempts to understand the mechanisms of infection better. The scientific community is working relentlessly to find a cure for COVID-19. The COVID-19 was tested using the most recent genetic and molecular research technologies. Personalized medication research and reagent production will expand further.
This research report on the European antibiotics market has been segmented and sub-segmented based on the following categories.
By Action Mechanism:
By Drug Class:
Geographically, The European antibiotics market is estimated to account substantial share in the global market during the forecast period. Despite growing global concern over antimicrobial resistance in humans due to antibiotics in animals, meat intake is rising year after year. According to the Organization for Economic Cooperation and Development (OECD), Russia has the largest intake of poultry meat. The market growth is attributed to the high consumption of antibiotics, prevalence of infectious diseases, and growing number of collaborations between government and private pharmaceutical companies. The Europe Antibiotics market is projected to record a CAGR of 2.8% during the forecast period 2021 to 2026. UK, Germany, France, Spain, and Italy are the major market contributors in the region.
In Europe, the German antibiotics market had accounted for the leading share in this regional market. Growing bodies to invest in research and development, development of novel antibiotics, and supportive regulatory policies in the country are expected to drive the market growth. Germany is anticipated to contribute to the European regional market with the influencing growth factors in the coming years. Germany is the leading cattle and pig feed producer with 7 million metric tons and 9.5 million metric tons of production.
The France antibiotics market is predicted to be another lucrative region for the antibiotics market in the European market and estimated to register healthy growth during the forecast period. France continues the lead in poultry feed production of 8.6 million metric tonnes. The rising livestock demand, along with rising feed production, will drive the market for feed premix. On the other hand, increasing livestock output and rising feed supply in the country is most likely to fuel the market for feed premix.
KEY MARKET PLAYERS:
Noteworthy companies dominating the European antibiotics market profiled in this report are Johnson and Johnson, GlaxoSmithKline, Pfizer PLC, Bayer AG, Novartis AG, Abbott Inc., Merck & Co. Inc., Sanofi SA, and F. Hoffmann-La Roche AG.